Showing results (1-10 of 162) with videos related to
Sort By:
Pageof 17
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 18, 2014
The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's diseaseChristian HölscherBiochemical Society Transactions|July 27, 2011
Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's diseaseChristian HölscherThe Journal of Endocrinology|September 4, 2013
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseasesChristian HölscherSheng Li Xue Bao : [Acta Physiologica Sinica]|October 22, 2014
Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseasesChristian HölscherFrontiers in Synaptic Neuroscience|August 15, 2022
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseasesChristian HölscherBiochemical Society Transactions|March 21, 2014
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseasesChristian HölscherReviews in the Neurosciences|September 30, 2003
Time, space and hippocampal functionsChristian HölscherCNS Drugs|September 4, 2012
Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotectionChristian HölscherInternational Review of Neurobiology|August 29, 2020
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseasesChristian HölscherVitamins and Hormones|November 25, 2010
The role of GLP-1 in neuronal activity and neurodegenerationChristian HölscherPageof 17